Lysosomal protease deficiency or substrate overload induces an oxidative-stress mediated STAT3-dependent pathway of lysosomal homeostasis

Jonathan Martínez-Fábregas1, Alan Prescott1, Sander van Kasteren2, Deena Leslie Pedrioli3,7, Irwin McLean3, Anna Moles4,8, Thomas Reinheckel5, Valeria Poli6 & Colin Watts1

Diverse cellular processes depend on the lysosomal protease system but how cells regulate lysosomal proteolytic capacity is only partly understood. We show here that cells can respond to protease/substrate imbalance in this compartment by de novo expression of multiple lysosomal hydrolases. This response, exemplified here either by loss of asparagine endopeptidase (AEP) or other lysosomal cysteine proteases, or by increased endocytic substrate load, is not dependent on the transcription factor EB (TFEB) but rather is triggered by STAT3 activation downstream of lysosomal oxidative stress. Similar lysosomal adaptations are seen in mice and cells expressing a constitutively active form of STAT3. Our results reveal how cells can increase lysosomal protease capacity under ‘fed’ rather than ‘starved’ conditions that activate the TFEB system. In addition, STAT3 activation due to lysosomal stress likely explains the hyperproliferative kidney disease and splenomegaly observed in AEP-deficient mice.
Endosomes and lysosomes are now known to participate in multiple aspects of cell and tissue physiology besides their classical role in degradation of endocytosed substrates. They host key signalling systems such as the nucleic acid sensing Toll-like receptors (TLRs)\(^1\)\(^-\)\(^4\) and mTOR pathway\(^3\)\(^-\)\(^4\), and they generate immunological information through class II MHC-mediated antigen presentation\(^5\)\(^-\)\(^6\). Lysosomal proteases can drive a physiologically important caspase-independent cell death pathway\(^7\)\(^-\)\(^8\), and lysosome-like organelles allow cytolytic leukocytes such as CD8 T cells, mast cells and eosinophils to execute their specific functions\(^9\). In addition, lysosomes are central to autophagy\(^10\)\(^-\)\(^11\). Most of these functions depend on protease activities found in the lysosomal lumen. Because these hydrolytic events are separated from the major cellular signalling pathways by the lysosomal membrane until recently it has not been obvious how a requirement for more or less hydrolytic capacity would be signalled to the cytosol and onwards to the transcriptional apparatus.

How lysosomal gene expression is controlled was advanced substantially by the identification of a signalling pathway that leads to the activation of transcription factor EB (TFEB)\(^12\)\(^-\)\(^13\). In response to cellular starvation, some types of lysosomal stress and some lysosomal storage diseases, TFEB translocated from the cytosol to the nucleus to drive the transcription of a variety of genes involved in lysosomal and autophagic function\(^13\)\(^-\)\(^14\). TFEB is negatively regulated by sequestration in the cytosol but in response to nutrient deprivation and reduced mTORC1 activity it becomes dephosphorylated, enters the nucleus and activates its target genes. In a PKC-dependent but mTORC1-independent pathway for TFEB activation was recently described\(^14\). As important as this pathway is, there are reasons to suspect that additional regulatory mechanisms of lysosomal hydrolytic capacity may exist. For example, an increase in lysosomal protein substrate load and/or the accumulation of undergraded protein substrates is not expected to induce the TFEB pathway since this would be more consistent with a ‘fed’ rather than starved state. Nonetheless, increased hydrolytic capacity is likely needed to restore the status quo but how this would be achieved in the absence of mTOR/TFEB signalling is not clear.

Deletion of individual murine lysosomal proteases results in clear tissue-specific phenotypes illustrating that they have non-redundant functions\(^15\)\(^-\)\(^18\). Lysosomal proteolytic capacity relies mainly on three different enzyme families: the papain-like cysteine proteases (e.g. cathepsins B and L), the pepsin-related aspartyl proteases (cathepsins D and E) and a distinct cysteine protease known as asparaginyl endopeptidase (AEP) or legumain\(^19\)\(^-\)\(^21\). AEP shows high specificity for cleavage after asparagine\(^19\)\(^-\)\(^20\), suggesting it has specific processing functions. Consistent with this, AEP has been shown to make activating cleavages in TLR9 and TLR7 in dendritic cells\(^1\)\(^-\)\(^22\), and to participate in antigen processing\(^23\). AEP has also been recently linked to both exitoneurotoxicity and to neurofibriillary pathology through its site-specific cleavage of the DNAse inhibitor SET and tau, respectively\(^24\)\(^,\)\(^25\). Mice lacking AEP develop hyperproliferative kidney disease\(^26\) and several indications of hemophagocytic lymphohistiocytosis including hepatosplenomegaly\(^27\). How the absence of AEP triggers these hyperproliferative states is not known, but AEP is particularly abundant in the kidney proximal tubule\(^19\)\(^,\)\(^26\).

We demonstrate here a TFEB-independent, STAT3-dependent signalling pathway for lysosomal protease homeostasis triggered by loss of lysosomal cysteine proteases or substrate overload. Chronic or acute AEP-deficiency promotes STAT3-dependent transcription of all three lysosomal protease families including AEP itself as well as other hydrolases. Lysosomal oxidative stress appears to be the primary driver of Jak2-STAT3 activation which is also observed in the AEP-deficient kidney proximal tubular system and which may explain the hyperproliferative disease and loss of kidney function in AEP-null mice.

**Results**

The lysosome detects loss of AEP activity and responds by increasing expression of multiple proteases. Deletion of AEP in the murine kidney leads to proximal tubular cell (PTC) hyperplasia, interstitial fibrosis and eventually loss of kidney function\(^26\). At the morphological level lysosomes appeared more prominent in AEP-null kidney PTC and cathepsin D (CtsD) staining was more intense (Fig. 1a, b) indicating accumulation of undegraded material and/or increased expression of lysosomal proteins. Indeed, the levels of CtsL, which accumulates in its active single chain (SC) form when AEP is absent\(^26\)\(^,\)\(^28\) and other hydrolases such as the active single chain form of CtsD were higher in AEP-null kidney (Fig. 1c).

We investigated this further using kidneys from mice fed a diet where \(^12\)C\(_6\)-lysine is replaced by \(^13\)C\(_6\)-lysine (‘SILAM mice’\(^29\)) to reveal the proteome of age-matched wildtype (WT) and AEP-null kidney lysosomes (Supplementary Fig. 1a). In addition to proteins we previously detected by 2D-difference gel analysis\(^26\) including SOD1, transthyretin (Ttr) and Ym1 (Figs. 1c, d, e and Supplementary Data 1), mass spectrometric and bioinformatic analysis using the SILAM kidney as a reference sample revealed a striking increase in multiple proteins associated with lysosomes and peroxisomes in the AEP-null kidney (Figs. 1d, e and Supplementary Data 1) including cathepsins (Cts) A, B, C, L and Z and other hydrolases such as hexosaminidase A and hexosaminidase B, beta mannosidase (Manba) and ganglioside GM2 activator (Gm2a). We validated these changes by direct western blotting of WT and AEP-null kidney lysates (Fig. 1c). Although there was a modest increase in Lamp1 it appeared to be lysosomal contents rather than lysosomal membrane proteins that were increased. Although some differentially represented proteins may be undegraded AEP substrates, for example, fibronectin (Fln1)\(^30\), the general increase in hydrolyase levels indicated an unexpectedly coordinated response to deletion of AEP.

This response was not specific to the kidney or to the in vivo state because many of the same proteins such as Gns and CtsD were elevated in SILAC-labelled AEP-null mouse embryonic fibroblasts (MEF; Fig. 1e and Supplementary Fig. 1b). Consistent with these changes, direct protease activity measurements in cell lysates (Fig. 1f) and in intact MEF (Supplementary Fig. 1c) confirmed enhanced CtsD/E and CtsB/L activity in AEP-null MEF. Moreover, the response could be induced acutely by treatment of WT MEF with the AEP inhibitor MVO26630, (hereafter MVO)\(^31\) which led to increased Gns, CtsD and importantly AEP itself (Fig. 1e, Supplementary Fig. 1a, b and Supplementary Data 1), To assess reversibility of the phenotype, we reconstituted AEP-null MEF with pro-AEP which is taken up by AEP-null MEF (Fig. 1g). Restoration of AEP activity reversed the accumulations seen in AEP-null MEF (Fig. 1e).

Increased protease levels was due to a transcriptional response because chemical AEP inhibition increased mRNA levels of AEP, CtsD and CtsL while genetic deletion of AEP induced even more substantial mRNA increases for CtsD and CtsL (Fig. 1g). Thus, loss of AEP activity promotes its own biosynthesis alongside several other lysosomal hydrolases.

**Increased lysosomal proteolytic capacity induced by suppression of AEP activity.** These results suggested an interesting and potentially important prediction: AEP ablation might actually lead to faster degradation of substrates traversing the endocytic

---

**NATURE COMMUNICATIONS** | https://doi.org/10.1038/s41467-018-07741-6 | www.nature.com/naturecommunications
pathway. We tested this for an exogenously supplied substrate and for two endogenous receptors. WT 3T3 fibroblasts, previously incubated with MVO to block AEP activity, were loaded with DQ-BSA, whose fluorescence is quenched prior to protease action. As shown in Fig. 3a, MVO-treated 3T3s showed stronger fluorescence compared with untreated 3T3s consistent with greater lysosomal protease capacity in the former. Moreover, ligand-induced downregulation of oncostatin M receptor beta (OSMRβ) and EGFR was faster in AEP-null and MVO-treated WT MEF compared with WT MEF (Fig. 3b, c). Thus, unexpectedly, genetic or chemical ablation of AEP elicits a response which, overall, leads to increased lysosomal proteolytic capacity.

Fig. 1 In vivo SILAC labelling reveals elevated lysosomal hydrolase expression induced by lack of AEP. a Transmission electron microscopy of WT (upper panel) and AEP−/− (lower panel) kidney sections. Arrows indicate lysosomes. (Scale bar = 2 μm) b Immunofluorescence showing more prominent lysosomes (CtsD, green) in AEP−/− kidney sections (lower panel) compared to WT kidney sections (upper panel). (Scale bar = 20 μm). c Western blot analysis confirming the accumulation in AEP−/− kidneys of proteins identified by mass spectrometry. d Volcano plot showing proteins over-represented (blue dots, lysosomal proteins highlighted in yellow) or under-represented (red dots) in AEP−/− lysosomal kidney fractions against the −log10 p-value for three independent experiments. Dotted line on y axis indicates p value < 0.05. e Acute AEP inhibition with MVO26630 recapitulates hydrolase induction in WT MEF and AEP reconstitution reverses it in AEP−/− MEF. f Induction of CtsD/E and CtsB/L activities in AEP−/− MEF compared to WT MEF. Data are the average ± SD of n = 4 biologically independent samples for CtsD/E or n = 3 biologically independent samples for CtsB/L. Statistical significance was calculated using a two-sided unpaired t-test. g Semi-quantitative RT-PCR analysis of mRNA levels for different cathepsins in WT MEF, WT MEF treated overnight with 50 μM MVO26630 and AEP−/− MEF. Data are the average ± SD of n = 3 biologically independent samples. Statistical significance was calculated using a Dunnett’s multiple comparison test.
AEP suppression triggers a TFEB-independent increase in lysosomal hydrolyase expression. We performed various experiments to test whether the upregulation of lysosomal hydrolysases following AEP inhibition was due to a TFEB response\(^\text{[11,13]}\). First, we generated cells expressing TFEB-GFP and challenged them either with MVO or with the mTORC1 inhibitor Torin1. For these and some subsequent experiments, we utilised the human kidney PTC line, HKC-8\(^\text{[33]}\). As previously reported\(^\text{[34]}\), TFEB-GFP showed a striking redistribution from cytosol to nucleus upon mTORC1 inhibition (Fig. 4a). In contrast, TFEB remained cytosolic in MVO-treated MEF (Fig. 4a) and in AEP-null kidney PTC (Fig. 4b). In fact, in the latter case TFEB seemed to be excluded from the nucleus to a greater extent compared to WT PTC. This suggested elevated mTORC1 activity and indeed phospo-4EBP1 levels were higher in AEP-null kidney (Fig. 4c). Reduced mTORC1 activity leads to TFEB-null kidney to a greater extent compared to WT PTC. In fact, in the latter case TFEB seemed to be cytosolic in MVO-treated MEF (Fig. 4a) and in AEP-null kidney PTC (Fig. 4b). In contrast, LC3 status, and therefore autophagy, was unchanged upon AEP inhibition (Fig. 4d). To investigate this apparent TFEB-independent response further, we used CRISPR-Cas9 technology to eliminate TFEB expression in HKC-8 cells (Supplementary Fig. 3a). As expected, upon starvation TFEB-null cells no longer induced an increase in cathepsin expression (Supplementary Fig. 3b). In contrast, when the same TFEB-null cells were treated with MVO, there was still a robust increase in expression of CtsD and CtsB at both protein (Fig. 4e) and mRNA (Fig. 4f and Supplementary Fig. 3c) levels. Thus increased lysosomal hydrolytic capacity did not in this instance involve a TFEB response.

Activation of STAT3 in AEP-deficient cells. Further analysis of cytosolic fractions from SILAC-labelled AEP-null MEF revealed a consistent increase both in the level and activation state of the transcription factor STAT3 (Fig. 5a, Supplementary Fig. 4a and Supplementary Data 1). Moreover, inhibition of AEP in WT MEF with MVO or with two other mechanistically distinct AEP inhibitors\(^\text{[35]}\) induced a dose-dependent increase in activated STAT3 (phospho-Tyr705-STAT3, hereafter P-STAT3) without affecting the levels of total STAT3 (Fig. 5a and Supplementary Fig. 4b). Importantly, P-STAT3 levels were already elevated in AEP-null MEF and were not further increased by MVO demonstrating that STAT3 was activated specifically by suppression of AEP activity (Fig. 5a). Phosphorylation of STAT3 on Tyr705 results in dimerisation and translocation into the nucleus\(^\text{[36]}\). P-STAT3 was found in the nuclei of AEP-null MEF and MVO-treated WT MEF but not untreated MEF (Fig. 5b). Similarly, in HKC-8 expressing STAT3-YFP, suppression of AEP activity clearly triggered nuclear translocation of STAT3 (Fig. 5b). MVO-treatment of HKC-8 cells also induced a dose-dependent increase in P-STAT3 (Fig. 5c).

STAT3 mediates the lysosomal response to loss of AEP activity. The notion that STAT3 rather than TFEB might control lysosomal hydrolyase expression under some conditions seemed plausible since a STAT3-dependent increase in the expression of several cathepsins during the involution of the mammalian mammary gland was recently shown\(^\text{[7,8]}\). We took multiple approaches to establish a link between STAT3 activation and lysosomal hydrolyase expression in our system. Small molecule targeting of STAT3 with S3I-201\(^\text{[37]}\) not only blocked STAT3 phosphorylation but almost completely reversed the MVO-induced increase in CtsD and CtsB levels in MEF (Fig. 5d and Supplementary Fig. 5a). To confirm these results, we generated STAT3-depleted HKC-8 cells by siRNA knockdown (Fig. 5e and Supplementary Fig. 5b). Knockdown of STAT3 by two different siRNAs suppressed the MVO-induced increase in CtsB and CtsD protein levels, a result not seen with a non-targeting siRNA control (Fig. 5e and Supplementary Fig. 5b). Further, we also generated a STAT3 mutant (fused to GFP to distinguish it from endogenous STAT3) designed to resist siRNA knockdown (mSTAT3-GFP). MVO-induced induction of CtsD was rescued in cells expressing mSTAT3-GFP, which in contrast to endogenous STAT3, was largely resistant to siRNA knockdown (Supplementary Fig. 5c) demonstrating unequivocally a requirement for STAT3. Consistent with canonical activation of STAT3,
inhibition of Jak2 with the inhibitor SD-1029 suppressed MVO-induced STAT3 phosphorylation (Fig. 5f and Supplementary Fig. 5d). Moreover, MVO treatment of HKC-8 cells activated Jak2, as indicated by enhanced phosphorylation on Tyr1007/1008 (Fig. 5g). To confirm the involvement of Jak2, we generated Jak2-depleted cells. As shown in Fig. 5h and Supplementary Fig. 5e, two different siRNAs directed to Jak2, but not a non-targeting siRNA, suppressed MVO-induced STAT3 phosphorylation as well as increased levels of CtsB and CtsD protein (Fig. 5h and Supplementary Fig. 5e). Thus, ablation of AEP activates the canonical Jak2-STAT3 pathway and leads to upregulation of other lysosomal hydrolases.

Direct promotion of lysosomal hydrolase expression by STAT3. Overall, 67% of proteins increased 1.5-fold or more in AEP-null MEFs featured a canonical STAT3 site in their promoters while almost 90% contained either canonical or non-canonical STAT3 sites as defined in a recent study38. Although this was consistent with STAT3 recruitment to lysosomal hydrolase promoters it was important to test this directly in AEP−/− versus WT cells. We immunoprecipitated STAT3-associated chromatin fragments (ChIP) from WT and AEP−/− MEF and compared the signal obtained by PCR from input versus precipitated DNA for key upregulated hydrolase genes. We observed enhanced STAT3 recruitment to the promoters of CtsD, CtsI, the still intact promoter region of the AEP gene and other hydrolase genes in AEP−/− compared with WT cells (Fig. 6a, b and Supplementary Fig. 6a). STAT3 recruitment to the AEP promoter made sense of the initially puzzling observation that low levels of MVO increased, rather than decreased AEP activity in cells. Blockade of STAT3 with S3I-201 prevented this increase and increased MVO potency at all concentrations (Fig. 6c). Taken together, these results demonstrate direct involvement of STAT3 in regulation of lysosomal hydrolase expression when a key lysosomal hydrolase activity is missing. Importantly, elevated activity of AEP and CtsD was also observed in 3T3 fibroblasts (Fig. 6f) expressing a constitutively active form of STAT3, STAT3c, which dimerises in the absence of tyrosine phosphorylation39,40, an increase which was again due to increased protease mRNA levels in these cells (Fig. 6d and Supplementary Fig. 6b).

Protein overload induces STAT3-dependent protease expression. If the response triggered by AEP ablation is due to accumulation of undegraded substrates, we reasoned that a similar response should be induced by substrate overload of the endocytic pathway. To test this WT MEFs were incubated for 16 h with 30 mg/ml BSA and the status of STAT3 as well as protease

**Fig. 3** Increased lysosomal proteolytic capacity induced by suppression of AEP activity. a) FITC-BSA uptake and DQ-BSA degradation rates in WT 3T3s treated (red circles) or untreated (blue squares) with 50 μM MVO26630 for 16 h. Data are means ± SEM of n = 8 microscopic fields for untreated and n = 15 microscopic fields for MVO-treated. (Scale bar = 20 μm). b) Time course of degradation of oncostatin M receptor beta (Osmrβ) in WT MEFs treated (dashed grey line) or untreated (black solid line) with 50 μM MVO26630 for 16 h and AEP−/− MEFs (red solid line) following receptor downregulation by oncostatin M. Relative intensity of each Osmrβ band was calculated for three independent experiments. c) Time course of degradation of epithelial growth factor receptor (EGFR) in WT MEFs treated (dashed grey line) or untreated (black solid line) with 50 μM MVO26630 for 16 h and AEP−/− MEFs (red solid line) following receptor downregulation by epithelial growth factor. Relative intensity of each EGFR band was calculated for three independent experiments. Statistical significance was calculated using a two-sided unpaired t-test. ns = not significant.
**Fig. 4** Increased lysosomal hydrolytic capacity induced by chronic or acute AEP-deficiency does not depend on TFEB activation. 

**a** Cellular localisation of TFEB-GFP in HKC-8 cells treated or untreated with 50 μM MVO26630 or 1 μM Torin1 overnight. (Scale bar = 20 μm). Data are the average ± SD of n = 93 cells for control sample, n = 48 for Torin1-treated sample and n = 92 for MVO-treated sample. Statistical significance was calculated using a Dunnett’s multiple comparison test. 

**b** Localisation of TFEB by IF in WT and AEP−/− kidney sections. (Scale bar = 20 μm). 

**c** Levels of P-4EBP1 by IF in WT and AEP−/− kidney sections. (Scale bar = 20 μm). 

**d** Immunoblotting and quantitation of LC3II/total LC3 ratio in lysates from WT MEFs treated with Rapamycin (1 μM) or Torin1 (1 μM) for 4 h or with MVO26630 (50 μM) for 16 h. Data are the average ± SD of n = 5 biologically independent samples. Statistical significance was calculated using a Dunnett’s multiple comparison test. 

**e** Levels of expression of CtsB and CtsD in HKC-8 WT and TFEB knockout Exon 1 treated or untreated with 50 μM MVO26630 for 16 h. Data are the average ± SD of n = 7 biologically independent samples for CtsB and n = 7 biologically independent samples for CtsD. Statistical significance was calculated using a two-sided unpaired t-test. 

**f** mRNA expression levels for CtsB and CtsD in HKC-8 WT and TFEB knockout Exon 1 treated or untreated with 50 μM MVO26630 for 16 h. Data are the average ± SD of n = 3 biologically independent samples. Full data and gel calibration markers can be seen in Supplementary Fig. 3c. Statistical significance was calculated using a two-sided unpaired t-test.
mRNA levels and activities assessed. Protein overload led to a two to sevenfold increase in the mRNA levels of several lysosomal proteases including AEP, CtsB, CtsL, CtsD and CtsH (Fig. 6e and Supplementary Fig. 7) consistent with an increase in protease activity levels (Fig. 6g). This increase was blunted by STAT3 inhibition with S3I-201 (Fig. 6g). Importantly, increased protein load also led to a striking increase in nuclear P-STAT3 similar to that seen upon MVO-treatment (Fig. 6h) but without nuclear translocation of TFEB (Supplementary Fig. 8a). In contrast, mTORC1 inhibition with either rapamycin or Torin1 had no
Fig. 5 Increased lysosomal hydrolytic capacity induced by chronic or acute AEP-deficiency is controlled by the Jak2-STAT3 signalling pathway. a STAT3 activation in WT but not AEP−/− MEFs treated for 16 h with increasing concentrations of MVO26630. Data are the average ± SD of n = 3 biologically independent samples. Statistical significance was calculated using a Dunnett’s multiple comparison test. b P-STAT3 localisation in WT and AEP−/− MEFs treated or not with 50 μM MVO26630 for 16 h (endogenous P-STAT3) and HKC-8 cells transfected with STAT3-YFP and treated or not with 50 μM MVO26630 for 16 h. Data are the average ± SEM of n = 96 cells for control samples and n = 86 for MVO-treated samples. Statistical significance was calculated using a two-sided unpaired t-test. (Scale bar = 20 μm). c STAT3 activation in HKC-8 cells treated with increasing levels of MVO26630. Data are the average ± SD of n = 3 biologically independent samples. Statistical significance was calculated using a two-sided unpaired t-test. d CtsD, CtsB and P-STAT3 levels in WT MEFs compared to WT MEFs treated overnight with 50 μM MVO26630 with or without 100 μM of the STAT3 inhibitor S3I-201. Data are the average ± SD of n = 3 biologically independent samples. Statistical significance was calculated using a two-sided unpaired t-test. e Levels of STAT3, CtsB and CtsD in WT HKC-8 cells transfected with a non-targeting siRNA (NT) or two different STAT3-targeting siRNAs (#8 and #10) and treated or not with 50 μM MVO26630 for 16 h. Data are the average ± SD of n = 3 biologically independent samples. Statistical significance was calculated using a Dunnett’s multiple comparison test. f P-STAT3 western blot in WT HKC-8 treated with 50 μM MVO26630 in the presence or absence of the Jak2 inhibitor SD-1029 (10 μM). Data are the average ± SD of n = 3 biologically independent samples. Statistical significance was calculated using a two-sided unpaired t-test. g Levels of P-Jak2 in WT HKC-8 cells treated or untreated with 50 μM MVO26630 for 16 h. Data are the average ± SD of n = 3 biologically independent samples. Statistical significance was calculated using a two-sided unpaired t-test. h Levels of Jak2, P-STAT3, CtsB and CtsD in WT HKC-8 cells transfected with a non-targeting siRNA (NT) or two different Jak2-targeting siRNAs (#6 and #7) and treated or not with 50 μM MVO26630 for 16 h. Data are the average ± SD of n ≥ 3 biologically independent samples. Statistical significance was calculated using a two-sided unpaired t-test.

Effect on P-STAT3 distribution but instead triggered focalised LC3 accumulation on autophagosomes, a response that was not observed either with MVO-treatment or protein overload (Fig. 6h). This important result demonstrates that STAT3-driven expression of lysosomal hydrolyases is not a limited response to the perturbations caused by loss of AEP activity but one induced by increased load on the lysosomal system and therefore likely to be of widespread physiological significance. Moreover, the activation of P-STAT3 and suppression of mTORC1 activity which activates TFEB does not occur when LVS also induced oxidative stress significantly. Consistent with this scenario, SOD1 levels were elevated in both AEP-null kidney26 and MEF (Fig. 1c, d and Fig. 7a), and SOD1 activity was also boosted following acute AEP inhibition with MVO (Fig. 7b). We strengthened the link between AEP-deficiency, oxidative stress and STAT3 activation in three ways. First, the ‘spin trap’ anti-oxidant phenyl-a-tet butyl nitrore (PBN) completely blocked the activation of STAT3 (Fig. 7c). Second, direct exposure to H2O2 induced the nuclear translocation of STAT3-YFP but not TFEB-GFP in HKC-8 cells (Fig. 7d) and moreover, increased the level of CtsD (Fig. 7e). Indeed, in H2O2 treated MEF, increased mRNA levels for multiple lysosomal proteases were observed (Fig. 7f and Supplementary Fig. 7). Third, CellROX Orange, a reporter dye that fluoresces upon oxidation showed a twofold increase in lysosomal labelling in AEP-null MEF and in WT MEF treated with MVO compared to untreated WT MEFs (Fig. 7g), thus identifying lysosomes as sites of ROS generation. Importantly, protein overload of lysosomes also induced oxidative stress signals in lysosomes (Supplementary Fig. 8b), underlining that STAT3 activation by lysosomal stress is a general response aimed at recovering lysosomal homoeostasis induced by lysosomal protease/substrate imbalance.

Lysosomal stress triggers STAT3-dependent de novo protease expression. STAT3 can be activated by a variety of exogenous and endogenous stimuli including oxidative stress41,42. We postulated that oxidative stress following acute AEP inhibition might be a driver of STAT3 activation since oxidative stress is a common feature of lysosomal storage diseases43. Consistent with this scenario, SOD1 levels were elevated in both AEP-null kidney26 and MEF (Fig. 1c, d and Fig. 7a), and SOD1 activity was also boosted following acute AEP inhibition in WT MEF (Fig. 7b). We strengthened the link between AEP-deficiency, oxidative stress and STAT3 activation in three ways. First, the ‘spin trap’ anti-oxidant phenyl-a-tet butyl nitrore (PBN) completely blocked the activation of STAT3 (Fig. 7c). Second, direct exposure to H2O2 induced the nuclear translocation of STAT3-YFP but not TFEB-GFP in HKC-8 cells (Fig. 7d) and moreover, increased the level of CtsD (Fig. 7e). Indeed, in H2O2 treated MEF, increased mRNA levels for multiple lysosomal proteases were observed (Fig. 7f and Supplementary Fig. 7). Third, CellROX Orange, a reporter dye that fluoresces upon oxidation showed a twofold increase in lysosomal labelling in AEP-null MEF and in WT MEF treated with MVO compared to untreated WT MEFs (Fig. 7g), thus identifying lysosomes as sites of ROS generation. Importantly, protein overload of lysosomes also induced oxidative stress signals in lysosomes (Supplementary Fig. 8b), underlining that STAT3 activation by lysosomal stress is a general response aimed at recovering lysosomal homoeostasis induced by lysosomal protease/substrate imbalance.

AEP ablation is linked to STAT3 activation in murine kidney PTC in vivo and in human PTC. To test the physiological relevance of the STAT3-driven response to lysosomal stress, we re-examined kidneys from AEP-null mice and mice expressing constitutively activated STAT3c. Indeed, levels of P-STAT3 were higher in AEP-null kidney compared with WT although levels of STAT3 protein appeared similar (Fig. 8a). Importantly, labelling for P-STAT3 was particularly prominent in the PTC, which exhibits the highest levels of AEP expression26 (Fig. 8b). This finding most likely explains the hyperproliferative PTC phenotype observed in AEP-null kidney26 and confirmed here using anti-Ki67 staining (Fig. 8c). Once again, increased expression of lysosomal hydrolyses could be uncoupled from AEP status since kidneys from STAT3c mice44 also showed striking increases in many of the proteins that were induced by AEP-deficiency or protein overload including CtsD and CtsL, Ym1, Gns and AEP (Fig. 8d). To test whether the response was conserved in primary human kidney cells, we expanded PTC as well as distal tubular cells (DTC) from biopsied human kidneys. MVO-treatment induced STAT3 activation and increased expression of CtsD in primary PTC but not in DTC (Fig. 8e).

STAT3 regulation of lysosomal capacity in cathepsin depleted cells and tissues. Finally, we addressed two further important questions: does ablation of lysosomal proteases besides AEP induce STAT3-driven hydrolase expression and do tissues other than the kidney show evidence of this response? First, we looked for an acute in vitro response akin to that induced by MVO by treating WT MEF with the cysteine cathepsin inhibitor E64 or the aspartyl cathepsin inhibitor pepstatin. WT MEF treatment with pepstatin increased P-STAT3 levels and boosted CtsD expression substantially as did E64 albeit to a lesser extent (Fig. 9a). Next, we examined tissues from mice genetically ablated for CtsL or B which are both CtsL targets. We examined heart since previous studies had demonstrated a cardiomyopathic phenotype in ageing CtsL-null mice and enlarged lysosomes in the myocardium45. In CtsL-null heart (Fig. 9b), P-STAT3 and CtsD levels were increased by at least a factor of 2 (Fig. 9b). Similar increases were observed in CtsB-null heart tissue although no overt heart phenotype has been described in these mice. Moreover, as in cells and tissues lacking AEP, SOD1 expression was also increased in CtsL-null tissues providing evidence that oxidative stress was a factor once again (Fig. 9b). Thus, ablation of diverse lysosomal protease activities can induce a STAT3-regulated response whose purpose is presumably to restore homoeostasis.

Discussion

How cells tune the performance of their lysosomes to meet the demand placed on them has only recently been investigated. A particular challenge is to understand how the environment in the lysosomal lumen is sensed and communicated to cytosolic
signalling pathways and the transcriptional machinery. Our results show that when the capacity of the lysosome to ‘keep up’ with substrate load is compromised, either because of loss of a key hydrolytic activity or because of increased endocytic load, oxidative stress leads to activation of STAT3 and the de novo transcription of a variety of lysosomal hydrolases. Although the endpoint is similar, this pathway differs fundamentally from the recently elucidated mTORC1-TFEB pathway for lysosomal biogenesis.

A mechanism for enhancing lysosomal capacity independent of the mTORC1-TFEB pathway makes sense from several standpoints. In particular, the cellular response to nutrient poor conditions that promote autophagy would be expected to be different to the response to conditions which can be characterised as ‘nutrient rich’ where exogenous proteins are abundant. Recent studies have shown that cells can use bulk endocytic uptake pathways such as macropinocytosis to capture proteins and degrade them to meet nutritional demands and to drive cell proliferation. Under these conditions, enhanced generation of amino acids in the lysosomal lumen would be expected to maintain or even enhance mTORC1 activity precluding TFEB activation. Indeed, most likely as a result of enhanced lysosomal protein breakdown and amino acid availability, we observed tight retention of TFEB on lysosomes under conditions that induced STAT3 activation.

Although ‘nutrient poor’ and ‘protein nutrient rich’ conditions both benefit from enhanced lysosomal capacity, other aspects of cellular physiology in these states are quite different. For example,
a number of TFEB target genes are involved in autophagy\textsuperscript{13}. Induction of autophagy alongside increased lysosomal capacity makes sense under nutrient poor conditions but probably not under conditions of increased substrate load since this would likely overload and stress the lysosomal system still further. In fact, faced with lysosomal overload of undegraded substrates, it would make sense to temporarily inhibit constitutive autophagy which is ongoing in most cells\textsuperscript{49}. Consistent with this, there is extensive evidence that autophagy is indeed inhibited by STAT3, for example through an inhibitory interaction between protein kinase R and STAT3 and/or through suppression of beclin 1 synthesis\textsuperscript{50–52}.

The STAT3-driven pathway of increased lysosomal capacity was observed in different cell types and is likely to be a general response to lysosomal stress-induced by protease insufficiency/substrate accumulation. It may however be particularly relevant in the kidney whose PTC are tasked with reabsorption and processing of a continual macromolecule load present in the

**Figure Legends:**
- **a:** Graph showing SOD1 activity (fold change) across different conditions.
- **b:** Graph showing SOD1 activity (fold change) across different conditions.
- **c:** Graph showing P-STAT3 and GAPDH expression levels across different conditions.
- **d:** Images showing TFEB and STAT3 expression under various conditions.
- **e:** Western blot analysis of CtsD and GAPDH expression under different conditions.
- **f:** Graph showing mRNA (fold change) across different conditions.
- **g:** Images showing nuclear fluorescence intensity under different conditions.
lipofuscin laden vacuoles and oxidative damage to brain pericytes ronal ceroid-lipofuscinosis characterised by accumulation of another lysosomal protease, CtsD can lead to congenital neu-

glomerular ultrafiltrate. Faced with an increased protein load as occurs in proteinuria, PTC likely need to increase lysosomal capacity. Indeed, in focal segmental glomerulosclerosis (FSGS), a model of glomerular injury, proteinuria led not only to increased lysosome protein content but also to an apparently adaptive increase in some lysosomal proteases33. A mechanistic basis for this was not elucidated but based on our results it seems likely that proteinuria leads to lysosomal stress, activation of STAT3 in PTC and that this is the basis of increased biosynthesis of lyso-

Fig. 7 Reactive oxygen species: At the nexus between lysosomal hydrolytic capacity and STAT3 phosphorylation. a Superoxide dismutase 1 (SOD1) activity in WT and AEP−/− MEFs. Data are the average ± SD of n = 3 biologically independent samples. Statistical significance was calculated using a two-sided unpaired t-test. b SOX1 activity in WT MEFs treated for 16 h with increasing concentrations of MVO26630. Data are the average ± SD of n = 3 biologically independent samples. Statistical significance was calculated using a Dunnett’s multiple comparison test. c MVO26630-induced (6 h, 50 μM) STAT3 activation in the presence of increasing concentrations of alpha Phenyl-N-Tert Butyl Nitrore (PBN). Data are the average ± SD of n = 3 biologically independent samples. Statistical significance was calculated using a Dunnett’s multiple comparison test. d Cellular distribution of TFEB-GFP (upper panels) and STAT3-YFP (lower panels) in HKC-8 WT treated or untreated with 0.2 mM H2O2 for 16 h. Quantitative data show the nuclear fluorescence intensity per cell (n = 79 for TFEB control, n = 99 for TFEB + H2O2, n = 59 for STAT3 control and n = 58 for STAT3 + H2O2). Statistical significance was calculated using a two-sided unpaired t-test. (Scale bar = 20μm). e Levels of CtsD in HKC-8 WT cells treated with 0.2 mM H2O2 for 16 h. Data are the average ± SD of n = 3 biologically independent samples. Statistical significance was calculated using a two-sided unpaired t-test. f Quantitative PCR analysis of the mRNA levels encoding several different lysosomal proteases in WT MEFs treated or not with 0.2 mM H2O2 overnight. Data are the average ± SD of n = 4 biologically independent samples for all samples, except for CtsH where n = 3. Statistical significance was calculated using a two-sided unpaired t-test. g Live cell imaging of lysosomal production of reactive oxygen species using CellROX Orange (CRO) in AEP−/− or WT MEFs treated or not with 50 μM MVO26630 for 16 h. LysoTracker Green DND26 (LTG) was used as a lysosomal marker. Data represent the mean CRO intensity per lysosome normalised to lysosomal size in μm² (n = 1254 lysosomes for WT MEFs sample, n = 1413 lysosomes for WT MEFs + MVO sample and n = 1204 for AEP MEFs). (Scale bar = 10μm). Statistical significance was calculated using a Dunnett’s multiple comparison test.

GLomerular injury, proteinuria led not only to increased lysosome protein content but also to an apparently adaptive increase in some lysosomal proteases33. A mechanistic basis for this was not elucidated but based on our results it seems likely that proteinuria leads to lysosomal stress, activation of STAT3 and this is the basis of increased biosynthesis of lysosomal hydrolases. Activation of STAT3 as a result of lysosomal stress may explain some of the inflammatory features of proteinuric kidney disease. Linked to this, other studies have shown that protein overloaded proximal tubular cells express several vasoactive and inflammatory mediators34 and that the Jak/STAT pathway was activated following protein overload of PTC in vitro35. With a full complement of lysosomal protease genes available, resolution of lysosomal overload would be expected to extinguish the oxidative stress that drives STAT3 activation and consequently, return hydrolase transcription to normal levels. However, when a critical gene such as AEP is missing and accumulation of target substrates continues, STAT3 activation becomes chronic likely explaining the onset of the severe pro-

Mice and cell culture. WT and AEP−/− mice on a C57BL/6 background, generated as previously reported36, were bred and maintained under pathogen-free conditions under UK Home Office Project License PPL60/3851 and with project approval from the University of Dundee Ethical Review Committee. WT and AEP-null primary murine embryonic fibroblast (MEF) were generated from WT or AEP−/− mice as previously described36 and expanded using complete Dulbecco’s modified Eagle medium (DMEM) supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM l-glutamine, 1% pyruvate, 1% non-essential amino acids and 10% FBS. For protein overload experiments, wildtype MEF were incubated with bovine serum albumin (30 mg/ml) on coverslips for immunofluorescence experiments or in 6 well plates to measure lysosomal proteolytic activities. HKC-8, a human-derived prox-

Methods. All antibodies used in this manuscript were used a 1:1000 dilution when used for immunoblotting and 1:200 when used for immunofluorescence. Antibodies against P-STAT3 (D3A7), STAT3 (1246H), P-Jak2 (D2E12), Jak2 (3771A), P-ERK1/2 (23814), LC3 (D3U4C) and GAPDH (14C10) were obtained from Cell Signaling. Antibodies against Laminin (ab11357), CtsD (ab75852), CtsB (ab92955), Lamp1 (ab24170) and Fibronectin (ab199056) were purchased from AbCam. Anti-Ki67 (B56) obtained from BD Bioscience, anti-Gus (13044-1-AP) from ProteinTech, anti-TFEB (A305-673A) from Bethyl, anti-YM1 (60130) from Stem Cell Technologies, anti-EGFR (sc-03) from SantaCruz, anti-OSMR (3458-100) from R&D System and anti-SOD1 (3458-100) from BioVision.

Antibodies against P-STAT3 (D3A7), STAT3 (1246H), P-Jak2 (D2E12), Jak2 (3771A), P-ERK1/2 (23814), LC3 (D3U4C) and GAPDH (14C10) were obtained from Cell Signaling. Antibodies against Laminin (ab11357), CtsD (ab75852), CtsB (ab92955), Lamp1 (ab24170) and Fibronectin (ab199056) were purchased from AbCam. Anti-Ki67 (B56) obtained from BD Bioscience, anti-Gus (13044-1-AP) from ProteinTech, anti-TFEB (A305-673A) from Bethyl, anti-YM1 (60130) from Stem Cell Technologies, anti-EGFR (sc-03) from SantaCruz, anti-OSMR (3458-100) from R&D System and anti-SOD1 (3458-100) from BioVision.

Mice and cell culture. WT and AEP−/− mice on a C57BL/6 background, generated as previously reported36, were bred and maintained under pathogen-free conditions under UK Home Office Project License PPL60/3851 and with project approval from the University of Dundee Ethical Review Committee. WT and AEP-null primary murine embryonic fibroblast (MEF) were generated from WT or AEP−/− mice as previously described36 and expanded using complete Dulbecco’s modified Eagle medium (DMEM) supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM l-glutamine, 1% pyruvate, 1% non-essential amino acids and 10% FBS. For protein overload experiments, wildtype MEF were incubated with bovine serum albumin (30 mg/ml) on coverslips for immunofluorescence experiments or in 6 well plates to measure lysosomal proteolytic activities. HKC-8, a human-derived prox-

exhanced lysosomal production of reactive oxygen species using CellROX Orange (CRO) in AEP−/− or WT MEFs treated or not with 50 μM MVO26630 for 16 h. LysoTracker Green DND26 (LTG) was used as a lysosomal marker. Data represent the mean CRO intensity per lysosome normalised to lysosomal size in μm² (n = 1254 lysosomes for WT MEFs sample, n = 1413 lysosomes for WT MEFs + MVO sample and n = 1204 for AEP MEFs). (Scale bar = 10μm). Statistical significance was calculated using a Dunnett’s multiple comparison test.
Isolation of human primary proximal (PTC) and distal tubular cells (DTC).

Human kidneys cells were isolated from adult kidneys after surgical resection in accordance with the Research Ethics Committee guidelines and approval granted by the NRES Committee East Midlands-Derby (REC reference 13/EM/0311) as previously described. Informed patient consent was obtained as part of this approval. Kidney cortex was minced and digested with 1 mg/ml collagenase IV for 90 minutes at 37°C, then separated by density-gradient centrifugation. Tissue fragments were rinsed with RPMI, then plated as a two-layer Percoll gradient (2.5% glutaraldehyde, 10% Percoll). Sections (300 μm) were fixed in Karnovsky’s fixative (2.5% glutaraldehyde, 0.1% paraformaldehyde in PBS at room temperature for 20 min or with 100% methanol). Tissue sections were retrieved and separately washed twice in RPMI at 300× g. DTC were seeded on collagen-coated plates and cultured in DMEM/F-12, GlutaMAX, L-Glutamine, Penicillin, Streptomycin, and maintained in DMEM/F-12, GlutaMAX, and maintained in DMEM/F-12, GlutaMAX, L-Glutamine, Penicillin, Streptomycin. Similar proteins accumulate in STAT3c and AEP null mice.

Transmission electron microscopy. The kidney cortex was cut into small (1 mm thick) pieces, and immediately fixated in Karnovsky’s fixative (2.5% glutaraldehyde, 4% paraformaldehyde in 100 mM cacodylate buffer pH 7.2). After centrifugation at 300×g, the pellet was resuspended in RPMI and loaded in a two layer Percoll gradient (50%, 24.6%). Centrifugation at 1000×g for 25 min at 4°C produced three separate layers: a top layer containing DTC and a middle layer containing PTC were retrieved and separately washed twice in RPMI at 300× g. DTC were fixed and maintained in REGM BulletKIts media from Lonza supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin. Cells were used between passage 2 and 3. Phenotypic PTC and DTC confirmation was obtained by electron microscopy.

Enzymatic activity assays. Cell lysates were prepared in 0.2 M Na citrate buffer pH 4.0 containing 1% Triton X-100. To measure AEP and CtsB/L activities 20 μg of total protein were incubated in 200 μl assay buffer (0.2 M Na citrate buffer pH 4.0, 1 mM DT1) containing 10 μM AEP substrate [Z-Ala-Ala-Asn-7-amino-4-methyl coumarin (AMC)] or 10 μM CtsB/L substrate [Z-Phe-Arg-AMC], respectively. AMC release was quantified at 460 nm in a fluorescence plate reader (Fluorostar Optima, BMG Labcetch), and activities calculated as arbitrary units. CtsD/E activities were measured under the same conditions but using 50 μg of cell lysate, 10 μM CtsD/E substrate [MCA-Gly-Lys-Pro-Ile-Leu-Lys(Dnp)-D-Arg-NH2] and MCA release measured at 390 nm. Activities were calculated as arbitrary units.

Superoxide dismutase [Cu-Zn] (SOD1) activity was determined using 20 μg of total cell lysate (TBS plus 1% Triton X-100) from WT or AEP−/− MEF treated or untreated with different inhibitors using the Superoxide Dismutase Assay Kit following the manufacturer’s instructions (ScienCell Research Laboratories).

Immunofluorescence microscopy. Kidney sections were retrieved from cull WT and AEP−/− mice and fixed in 10% buffered formalin and embedded in paraffin blocks. Sections (3 μm thick) were cut, deparaffinised using Histo-Clear and subjected to antigen retrieval using pressure cooking in Na citrate buffer, pH 6.0. Sections were permeabilized with 1× TBS supplemented with 0.025% Triton X-100 and blocked with 10% FBS and 1% BSA in TBS prior to overnight staining at 4°C with the following primary antibodies prepared in TBS, 1% BSA: rabbit anti-P-4EBP1, rabbit anti-TFEB, rabbit anti-LC3B, rabbit anti-P-STAT3, mouse anti-Ki67, rabbit anti-laminin, rabbit anti-CtsD, rabbit anti-Gns, rabbit anti-TFEB, rabbit anti-P-4EBP1 (dilution 1:200). After washing in TBS 0.025% Triton X-100 twice, the slides were incubated for 1 h with the appropriate Alexa-488- or Alexa 594-conjugated secondary antibody (Invitrogen, dilution 1:500) in TBS with 1% BSA. The slides were finally washed three times in TBS and mounted under coverslips using Vectashield mounting medium containing DAPI (Vector Laboratories) and viewed using an LSM 700 confocal microscope (Carl Zeiss).

WT and AEP−/− MEF (5 × 104 cells/coverslip) were fixed with 4% paraformaldehyde in PBS at room temperature for 20 min or with 100% methanol at −20°C for 10 min. The cells were washed three times with PBS, permeabilized with 0.2% Triton X-100 in PBS for 20 min at room temperature, washed 3× with PBS and then incubated for 20 min at room temperature in blocking buffer (1% BSA in TBS). The cells were stained using a 1:200 dilution of primary antibody in blocking buffer for 45 min at room temperature (rabbit anti-TFEB, rabbit anti-LC3 or rabbit anti-P-STAT3), washed three times with PBS and stained with a 1:500 dilution of the Alexa-488-conjugated secondary antibody (Invitrogen) for another 45 min at room temperature. Coverslips were washed three times with PBS 1× and mounted using Vectashield mounting medium containing DAPI (Vector Laboratories) and viewed using an LSM 700 confocal microscope (Carl Zeiss).

![Image of kidney sections and immunofluorescence microscopy](https://example.com/image.png)

**Fig. 8** Activation of STAT3 in AEP−/− kidney and enhanced hydrolase expression in STAT3c kidneys. a STAT3 and P-STAT3 levels in WT and AEP−/− kidneys. b P-STAT3 detected by IF in WT and AEP−/− kidney sections. Right panel shows quantitation of the number of P-STAT3 positive nuclei per area (n = 35 microscopic fields). c Ki67 and laminin detected by IF in WT and AEP−/− kidney sections. (Scale bar = 20 μm). d Similar proteins accumulate in STAT3c and AEP−/− kidney. e Levels of P-STAT3 and CtsD in proximal (PTC) and distal (DTC) tubular cells treated or not with 50 μM MVO26630 overnight. Data are the average ± SD of n = 5 biologically independent samples for PTCs and n = 3 for DTCs. Statistical significance was calculated using a two-sided unpaired t-test.
STAT3-YFP and TFEB-GFP cellular distribution in HKC-8 cells. The TFEB-GFP construct was purchased from Acris Antibodies. STAT3-YFP was cloned into pcDNA5. HKC-8 cells (5 × 10⁴ cells/coverslip) were transfected with STAT3-YFP construct was purchased from Acris Antibodies. STAT3-YFP was cloned into STAT3-YFP and TFEB-GFP cellular distribution in HKC-8 cells

Fig. 9 Chronic or acute inhibition of cysteine or aspartyl cathepsins lead to a similar response. a Levels of P-STAT3 and CtsD in WT MEFS treated or not with 10 µM E64 or 5 µM Pepstatin A for 72 h. Data are the average ± SD of n = 4 biologically independent samples for P-STAT3 and n = 3 biologically independent samples for CtsD. Statistical significance was calculated using a two-sided unpaired t-test. b Levels of P-STAT3, STAT3, CtsD and SOD1 in CtsB<sup>−/−</sup> heart or CtsL<sup>−/−</sup> heart compared to WT heart. Data are the average ± SD of n = 3 biologically independent samples. Statistical significance was calculated using a two-sided unpaired t-test

STAP3-YFP and TFEB-GFP cellular distribution in HKC-8 cells. The TFEB-GFP construct was purchased from Acris Antibodies. STAT3-YFP was cloned into pcDNAs. HKC-8 cells (5 × 10⁴ cells/coverslip) were transfected with STAT3-YFP or TFEB-GFP using polyethyleneimine (PEI) and 24 h later cells were treated as indicated in the figure legends. After fixation with 4% paraformaldehyde in PBS at room temperature for 20 min the coverslips were washed three times with PBS 1× and mounted using Vectashield mounting medium containing DAPI (Vector Laboratories) and viewed using an LSM 700 confocal microscope (Carl Zeiss).

TFEB knockdown in HKC-8 cells. Two different TFEB knockouts were generated by targeting TFEB exon 1 or exon 2. The sense guides (exon 1: GCATCGAGCCATGCGGCC; exon 2: GTGCCCGAGCAGCTCCCA) were cloned into the pBABED puro U6 and the antisense guides were cloned into the Cas9 D10A vector pX355 (exon 1: GCAGCCCGATGCGTGACGCCA; exon 2: GTGCCCCAGCAGCATCCCCAG). HKC-8 cells (10⁶ cells/10 cm dish) were transfected with the sense and antisense guides targeting exon 1 or exon 2 of the TFEB gene using PEI. Twenty-four hours later the media was replaced with media supplemented with 2 µg/ml puromycin. After 48 h of puromycin selection transfected cells were expanded and individual clones were isolated and tested for TFEB expression by western blotting.

Jak2 knockdown in HKC-8 cells. A set of four Jak2-siRNAs were purchased from Dharmacon and tested individually to determine levels of knockdown achieved. The siRNAs providing the highest level of Jak2 knockdown (siRNA #8: CAAACUUGCAUUGCGUAGA and siRNA #10: CAAACAUUGCCUGAGUUG) were subsequently used in all the experiments. KC-8 cells (10<sup>4</sup> cells per well) in a 96 well plate were transfected with STAT3-siRNAs or non-targeting siRNA (UUGUUUACAUUGCAGCAUU) (Dharmacon) using DharmaFect 1 transfection reagent (Dharmacon) following the manufacturer’s instructions. Forty-eight hours later each well was treated as indicated and samples prepared for SDS-PAGE analysis.

To generate a form of STAT3 refractory to siRNA knockdown, we fused it to GFP to distinguish it from endogenous STAT3 (mSTAT3-GFP) and introduced mutations into the target sequence for siRNA #8 (see above) using the following primers 5′-GGAGCGATGAAACATGTCAATTTCCTTGAATTCATCATG-3′ and 5′-CATGATGATTTCAGCAATTGCATGTTGTTCAGCTGC-3′. HKC-8 cells were transiently transfected using PEI and GFP-positive cells were enriched by FACs using an Influx cell sorter (Becton Dickinson). Cells were distinguished from debris based on FSC-H vs SSD-H and single cells on the basis of FSC-A vs FSC-W measurements. GFP-positive cells were identified based on background fluorescence levels in the parental cell line negative control. Then, sorted cells were expanded for 48 h in the presence of G418 to maintain plasmid expression prior to SDS-PAGE analysis.

STAT3 knockdown and rescue in HKC-8 cells. A set of four STAT3-siRNAs were purchased from Dharmacon and tested individually to determine levels of knockdown achieved. The siRNAs providing the highest level of STAT3 knockdown (siRNA #8: CAAACUUGCAUUGCGUAGA and siRNA #10: CAAACAUUGCCUGAGUUG) were subsequently used in all the experiments. STAT3 knockdown (P<0.001) was observed using the ChIP assay with the anti-SOD1 antibody and a negative control antibody. STAT3 ChIP-PCR. Anti-STAT3 ChIP was carried out as previously described<sup>13</sup>. Briefly, WT and AEP<sup>−/−</sup> MEFS were grown to 70% confluence, crosslinked with 1% formaldehyde for 10 min at RT. Excess formaldehyde was blocked with 0.125 M glycine and the cells washed with ice-cold PBS several times after which the cells were scraped off in 2 ml of PBS containing protease inhibitors and collected by centrifugation at 500g for 10 min at 4 °C. Pellets were resuspended in lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris–HCl (pH 8.1) and protease inhibitors) and sonicated three times for 5 min in a BioRuptor RTH (30 s on/30 s off). Samples were then diluted 1:10 in ChIP dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris–HCl (pH 8.1)) and anti-STAT3 antibody was added to the samples (Cell Signaling, 124H6) and incubated overnight at 4 °C. Finally immunoprecipitated chromatin was purified using the iPure Kit (Diagenode) following the manufacturer’s instructions.
The samples were then tested for the presence of the promotor regions of genes of interest by PCR using the following primers:

**STAT3** (forward: GGTGACACTTGGGACCCGCTTAAG; reverse: AAAAAACCTCTTGGAGAGAAGGCG),

**AEP** (forward: ATGATTGTCGGGTGTTGTTGC; reverse: TCTGGGTTGGCGCTTCACCA),

**Ctd** (forward: AAAAACCTTCTCATGTCTTACAA; reverse: GGCCCTGCTGTGGATTTCCACTCC),

**CtsD** (forward: AGATGAGAAGTGTAAAGCCCAAG; reverse: AGGGAGCTTGCAACGGGAGAC),

**Gns** (forward: GGAAGGCTGCGACGCAAGGCAAAC; reverse: GGGACAGGAGCCGAGTACAGG),

**Manz2b** (forward: GATAGAGGAGACTGAGCTGGCT; reverse: CAGATATCAATTCGTTGCTTGA),

**Naga** (forward: GTTAAAGACAGTTCTTTGTCTGA; reverse: GGGCTGGCGGCTGCGC),

**Phld2** (forward: TGCAGAGGCTTTGCTTGAAC; reverse: CTGACGATCCTCCTTCACAGGA). The sequence of the primers used as negative controls was: (forward: ATGTTGTCAGCTTGGGATG; reverse: TGCCAAAGCTTGGGAGAGA) Electrophoretically separated PCR products were quantified with ImageJ and normalised to input samples.

**Generation of 13C6-Lysine SILAM mouse colony.** An in-house breeding colony of C57BL/6 13C6-Lysine ‘SILAM’ labelled mice was generated using specialised 13C6-Lysine mouse diet (slanters, Martinsried, Germany) following the breeding programme previously described by Krüger et al.29 Labelling efficiency was monitored for brain, liver and skin tissues from 16-week-old C57BL/6J mice fed 13C6-Lysine for 16 weeks. Labelling efficiency was calculated as: 100% (reference)/area (heavy peptide) x 100% of the area (light peptide). The 13C6-Lysine was labelled at the F2 generation. Tissues used for this study were acquired from F4 C57BL/6 13C6-Lysine SILAM females.

Kidney lysosome SILAC-based mass spectrometry. Kidney lysosomes from 13C6-Lysine labelled WT mice and unlabelled WT or AEP−/− mice were prepared as previously described.30 60 μg of unlabelled WT or AEP−/− kidney lysosomal proteins were combined in a 1:1 ratio with 60 μg of 13C6-Lysine labelled WT kidney lysosomal proteins. Protein samples were prepared for LC-MS/MS using the FASP protocol as previously described.30 Briefly, the protein mixture was room-temperature digested for 5 min in 500 μl of 50 mM NH4CO3 buffer (4% w/v SDS, 100 mM Tris–HCl pH 7.6, 0.1 mM DTT) and the samples were mixed with 200 μl of 8 M urea in 0.1 Tris–HCl pH 8.5 (UA buffer) in a Microcon YM-10 filter unit and centrifuged at 17,000g for 40 min. Samples were washed again with another 200 μl of UA buffer and then treated with 100 μl of 0.5 M iodoacetamide in UA buffer for 20 min at room temperature. After three further washes with 100 μl UA buffer and three times with 0.05 M NH4HCO3 (ABC buffer) centrifuging each time at 14,000g for 15 min and discarding the flow through, the protein mixture was digested overnight at 37° C in the YM-10 filter unit using 40 μl of 0.4 μg/ml trypsin in ABC buffer. The sample was treated with 50 μl of 50 mM iodoacetamide for 30 min and equal amounts of protein were separated by SDS-PAGE and subjected to direct Western blotting using anti-OSMR (Amersham). Membranes were probed with the following antibodies: rabbit anti-P-STAT3, mouse anti-STAT3, rabbit anti-GAPDH and rabbit anti-LC3 (Cell Signalling, Danvers, MA), rabbit anti-Yml1 (StemCell Technologies), rabbit anti-EGRF (Santa Cruz), rabbit anti-Lamp1, rabbit anti-CtsD, rabbit anti-F1 and anti-CtsB (abCam), rabbit anti-TFF-B (Bethyl) and rabbit anti-Gns (ProteinTech) and goat anti-OSMR (R&D Systems). Sheep anti-AEP was obtained as described previously56 and sheep anti-CtsD and CtsH were generous gifts from Drs Tsv Tsvazavilik Bergman and Janko Kos (Joal Stefan Institute, Ljubljana, Slovenia).

In vivo cathepsin L activity assay. WT and AEP−/− MEF (5 × 105 cells) were grown on coverslips and incubated with Magic Red cathepsin L (Immunochemistry Technologies) for 60 min at 37 °C following the manufacturer’s instructions. The cells were then fixed with 4% paraformaldehyde in PBS, mounted using Vectashield mounting medium containing DAPI (Vector Laboratories) and images were obtained using a LSM 700 confocal microscope (Carl Zeiss).

**Lysosomal degradation of DQ-BSA.** WT ST3 cells (5 × 104 cells) were grown on coverslips and treated with MVO 50 μM for 16 h. Then, cells were incubated with 10 μg/ml of DQ-BSA (Invitrogen) or 50 μg/ml of FITC-BSA for 2 h at 37 °C, washed twice with PBS, then fixed with 4% paraformaldehyde in PBS for 20 min at room temperature, mounted and counterstained with DAPI (Vector Laboratories) and images were obtained using an LSM 700 confocal microscope (Carl Zeiss).

**Onconstatin M receptor β (OSMRβ)** and epithelial growth factor receptor (EGFR) degradation assay. Total cell extracts from WT cells treated or not with 50 μM VIVO360 and AEP−/− MEF (2 × 105 cells), incubated as described with onconstatin M 25 ng/ml (R&D Systems) or epithelial growth factor 100 ng/ml and cycloheximide (10 μg/ml), were prepared in complete RIPA buffer and equal amounts of protein were separated by SDS-PAGE and subjected to direct Western blotting using anti-OSMRβ or anti-EGFR as described above.

**In-cell reactive oxygen species determination.** WT and AEP−/− MEF grown on FluoroView dishes (World Precision Instruments Inc.) treated as indicated with different inhibitors were incubated with 100 μM MitoTracker Deep Red FM (Molecular Probes) for 2 h at 37 °C and then with 2.5 μM CellROX Orange (Invitrogen) for 30 min at 37 °C. The cells were washed twice with PBS, fresh complete DMEM containing 2% FBS and 10 mM sodium acetate at 37 °C.
was added to the dishes and live cell imaging carried out at 37°C and 5% CO₂ using a LSM 700 confocal microscope (Carl Zeiss). CellBOX Orange intensity oversampling with the Volocity 3D Image Analysis Software (PerkinElmer). The mean intensity of CellBOX Orange per LysoTracker Green DND26 positive structure, normalised for lysosomal size (µm²) and per cell was calculated and the standard error calculated using 15 cells per experimental condition.

Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR).
Total RNA from WT MEF, treated or untreated with 50 µM MVO26630 overnight, and AEP−/− MEFS, WT and STAT3 3T3s was purified using RNeasy mini kit (Qiagen) following the manufacturer’s instructions. Total RNA concentration was determined using a NanoDrop 1000 spectrophotometer (Thermo) and 1 µg of total RNA per sample was used to synthesise cDNA using the qScript Flex cDNA kit (Quanta Biosciences) according to the manufacturer’s conditions. Finally, the mRNA expression levels of different lysosomal proteases were determined by PCR, quantified using ImageJ (imagej.nih.gov) and normalised using β-actin or Tubulin 5 as loading control. The following primers were used: β-actin: forward (ATCAGTGTGGACACCTTCACAG), reverse (CATCCTCTGCTGGAAGATCTCA); Tubb5: forward (TGGTACTAATATGGAACACCAGTTGG), reverse (CAGTAG GTCTCAGCTGGTTCCTCAA); AEP: forward (ATGACAGTGGAGAGGTCAGCT), reverse (GGTCTGAGTGCGCTGGGCA); Csβ: forward (GGGACTTGTAGGTCAGG), reverse (CCTAATGGCACCAAGAAGCC); Csδ: forward (GCTAG GGACCTCTCGGTGGTA), reverse (ATGAGGGAAGATGGTCTT); HSC: forward (ATGAGCAGGCTGGAATGGTT), reverse (CTCCCCGTGCT GCCAATC AG); CtsC: forward (ATGGCACGAGTTAGGAAAGAG), reverse (GGAAGACGCTCCCTTCCTTG) and CtsZ: forward (CACGGATCTCCCTCCTCCT), reverse (CCAGGGGAGGGGAAAACACAGA).

HCK-8 WT AND TFEB KOs Starvation.
Total cell extracts from HCK-8 WT and TFEB KO cells starved or not for 4 h in HBSS at 37°C and 10% CO₂ were prepared in complete RIPA buffer and equal amounts of protein were separated by SDS-PAGE and subjected to direct Western blotting using anti-LC3 or anti-Ctsβ as described above.

GO analysis.
ClueGo66 within the Cytoscape software66 was used to find statistically over-represented gene ontology (GO) categories. The identified proteins from the kidney lysosomal SILAC-based mass spectrometry analysis were used as a test dataset and a reference set of GO annotations for the mouse proteome was used in order to carry out the GO enrichment analysis. Analyses were done using a right-sided hypergeometric test and all GO terms corresponding to cellular location or molecular function with p < 0.005 were selected.

Data availability
The authors declare that all primary data are available in main or Supplementary figures. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD001473. All other data that support the findings of this study are available from the corresponding authors upon reasonable request.

Received: 6 August 2018 Accepted: 18 November 2018

References
1. Sepulveda, F. E. et al. Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. Immunity 31, 737–748 (2009).
2. Ewald, S. et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 456, 658–662 (2008).
3. Settembre, C. et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFE3. EMBO J. 31, 1095–1108 (2012).
4. Sabatini, D. M. Twenty-five years of mTOR: Uncovering the link from nutrients to growth. Proc Natl Acad Sci USA 114, 11818–11825 (2017).
5. Colbert, J. D., Mathur, S. P., Miller, G. & Watts, C. Diverse regulatory roles for lysosomal proteases in the immune response. Eur J. Immunol. 39, 2955–2965 (2009).
6. Bird, P. L., Tranapi, J. A. & Villadangos, J. A. Endolysosomal proteases and their inhibitors in immunity. Nat Rev. Immunol. 9, 871–882 (2009).
7. Ueckert, P. A. et al. Stat3 controls lysosomal-mediated cell death in vivo. Nat Cell Biol. 13, 303–310 (2009).
8. Sargeant, T. J. et al. Stat3 controls cell death during mammalian gland involution by regulating uptake of milk fat globules and lysosomal membrane permeabilization. Nat Cell Biol. 16, 1057–1068 (2014).
9. Luzio, J. P., Hackmann, Y., Dieckmann, N. M. G. & Griffiths, G. M. The biosynthesis of lysosomes and lysosome-related organelles. Cold Spring Harb. Perspect. Biol. 6, a016840 (2014).
10. Shen, H.-M. & Mizushima, N. At the end of the autophagic road: an emerging landscape of lysosomal dysfunction. Trends Biochem. Sci. 39, 61–71 (2014).
11. Sardiello, M. et al. A gene network regulating lysosomal biogenesis and function. Science 325, 473–477 (2009).
12. Ballabio, A. The awesome lysosome. EMBO Mol. Med. 8, 73–76 (2016).
13. Settembre, C. et al. TFE3 links autophagy to lysosomal biogenesis. Science 332, 1429–1433 (2011).
14. Li, Y. et al. Protein kinase C controls lysosome biogenesis independently of autophagy. Nat Cell Biol. 18, 1065–1071 (2016).
15. Spira, D. et al. Cell type-specific functions of the lysosomal protease cathepsin L in the heart. J. Biol. Chem. 282, 37045–37052 (2007).
16. Koike, M. et al. Cathepsin D deficiency induces lysosomal storage with cereoid lipofuscin in mouse CNS neurons. J. Neurosci. 20, 6898–6906 (2000).
17. Reiser, I., Adari, B. & Reischel, T. Specialized roles for cysteine cathepsins in health and disease. J. Clin. Invest. 129, 3421–3431 (2010).
18. Tholen, M. et al. Out-of-frame start codons prevent translation of truncated nucleo-cytosolic cathepsin L in vivo. Nature 5, 4931 (2014).
19. Chen, J. M. et al. Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J. Biol. Chem. 272, 8090–8098 (1997).
20. Manouy, B. et al. An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature 396, 695–699 (1998).
21. Dall, E. & Brandstetter, H. Mechanistic and structural studies on legumain – autoactivation of asparaginyl endopeptidase in vitro and in vivo. EMBO Rep. 8, e100284 (2012).
22. Watts, C., Matthews, S. P., Mazzeo, D., Manouy, B. & Moss, C. X. Asparaginyl endopeptidase: case history of a class II MHC compartment protease. Trends Cell Biol. 20, 214–221 (2010).
23. Watts, C., Matthews, S. P., Mazzeo, D., Manouy, B. & Moss, C. X. Lysosomal proteolysis of SET proteolytic degradation by asparaginyl endopeptidase. Mol Cell 29, 665–678 (2008).
24. Zhang, Z. et al. Cleavage of tau by asparaginyl endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease. Nat Med. 20, 1254–1262 (2014).
25. Miller, G., Matthews, S. P., Reineckel, T., Fleming, S. & Watts, C. Asparaginyl endopeptidase is required for normal kidney physiology and homeostasis. FASEB J. 25, 1606–1617 (2011).
26. Chan, C.-B. et al. Mouse lacking asparaginyl endopeptidase develop disorders resembling hemophagocytic syndrome. Proc Natl Acad Sci USA 106, 468–473 (2009).
27. Shirahama-Noda, K. et al. Biosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase-deficient mice. J. Biol. Chem. 278, 33194–33199 (2003).
28. Krüger, M. et al. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell 134, 353–364 (2008).
29. Miyagawa, Y. et al. Legumain/asparaginyl endopeptidase controls extracellular matrix remodeling through the degradation of fibronectin in mouse renal proximal tubular cells. FERS Lett. 581, 1417–1424 (2007).
30. Loak, K. et al. Novel cell-permeable acyloxymethylketone inhibitors of asparaginyl endopeptidase. Biol Chem. 384, 1239–1246 (2003).
31. Li, D. N., Matthews, S. P., Antoniou, A. N., Mazzeo, D. & Watts, C. Multistep autoactivation of asparaginyl endopeptidase in vitro and in vivo. J. Biol. Chem. 278, 38980–38990 (2003).
32. Turvey, M. R., Wang, Y. & Gu, Y. The effects of extracellular nucleotides on [Ca2+]i signalling in a human-derived renal proximal tubular cell line (HCK-8). J. Cell. Biochem. 109, 132–139 (2010).
33. Wang, W. et al. Up-regulation of lysosomal TRPML1 channels is essential for lysosomal adaption to nutrient starvation. Proc Natl Acad Sci USA 112, E1373–E1381 (2015).
35. Lee, J. & Bogoy, M. Synthesis and evaluation of aza-peptidyl inhibitors of the lysosomal asparaginyl endopeptidase legumain. Bioorg. Med. Chem. Lett. 22, 1340–1343 (2012).
36. Zhong, Z., Wen, Z. & Darnell, J. E. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264, 95–98 (1994).
37. Pang, M. et al. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibrosis and intestinal fibrosis in obstructive nephropathy. Kidney Int. 78, 257–268 (2010).
38. Hutchins, A. P. et al. Distinct transcriptional regulatory modules underlie tumor suppressor target gene expression by the p52 NF-κB subunit. EMBO J. 25, 4820–4832 (2006).
39. Wiśniewski, J. R., Zougman, A., Nagaraj, N. & Mann, M. Universal sample preparation method for proteome analysis. Nat. Meth. 6, 359–362 (2009).
40. Kim, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008).
41. Cox, J. et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794–1805 (2011).
42. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).

Acknowledgements
We thank Dr. Kamila Chughtai and Dr. Patrick Pedrioli for kindly monitoring SILAM labelling efficiency of the C57BL/6j 13C6-Lysine mouse colony and Rosie Clarke and Arlene Renee for cell sorting. We are grateful to Prof. N.S. Sheerin for access to human kidney tissues, Matt Bogoy for epoxide and Michael acceptor AEP inhibitors, Doreen Keane for technical assistance, Kenny Milne for mass spectrometry, Thomas Macartney for CRISPR-Cas9 vector design and Steve Matthews and Krzysz Wypijewski for comments on the manuscript. Generation and maintenance of protease-deficient mice was supported by SFB 850 project B7 and DFG grant RE1584/6-2 to T.R. V.P. was supported by AIRC Grant Number IG 16930. This work was funded by a Wellcome Trust Programme grant to C.W.

Author contributions
J.M.-F. designed, performed and analysed all experiments and wrote the paper. A.P. performed microscopy and helped with analysis of the micrographs. S.v.K. synthesised synthetic and natural inhibitors. Biochem. Biophys. Acta 1845, 136–154 (2014).

Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-018-07741-6.

Competing interests: The authors declare no competing interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.